Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Structure of the homodimeric androgen receptor ligand-binding domain
Marta Nadal, Stefan Prekovic, Nerea Gallastegui, et al.
Nature Communications (2017) Vol. 8, Iss. 1
Open Access | Times Cited: 170

Showing 1-25 of 170 citing articles:

Recent Advances in Prostate Cancer Treatment and Drug Discovery
Ekaterina Nevedomskaya, Simon J. Baumgart, Bernard Haendler
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 5, pp. 1359-1359
Open Access | Times Cited: 232
Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance
John A. Katzenellenbogen, Christopher G. Mayne, Benita S. Katzenellenbogen, et al.
Nature reviews. Cancer (2018) Vol. 18, Iss. 6, pp. 377-388
Open Access | Times Cited: 187
Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
Qin Feng, Bin He
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 159
Nuclear receptor crosstalk — defining the mechanisms for therapeutic innovation
Karolien De Bosscher, Sofie Desmet, Dorien Clarisse, et al.
Nature Reviews Endocrinology (2020) Vol. 16, Iss. 7, pp. 363-377
Closed Access | Times Cited: 155
Androgen insensitivity syndrome: a review
Rafael Loch Batista, Elaine Maria Frade Costa, Andresa De Santi Rodrigues, et al.
Archives of Endocrinology and Metabolism (2018) Vol. 62, Iss. 2, pp. 227-235
Open Access | Times Cited: 138
Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes
Xinzhe Yu, Ping Yi, Ross A. Hamilton, et al.
Molecular Cell (2020) Vol. 79, Iss. 5, pp. 812-823.e4
Open Access | Times Cited: 125
Natural Compounds in Prostate Cancer Prevention and Treatment: Mechanisms of Action and Molecular Targets
Fabrizio Fontana, M. Raimondi, Monica Marzagalli, et al.
Cells (2020) Vol. 9, Iss. 2, pp. 460-460
Open Access | Times Cited: 86
Quercetin and Its Nano-Scale Delivery Systems in Prostate Cancer Therapy: Paving the Way for Cancer Elimination and Reversing Chemoresistance
Yaseen Hussain, Sepideh Mirzaei, Milad Ashrafizadeh, et al.
Cancers (2021) Vol. 13, Iss. 7, pp. 1602-1602
Open Access | Times Cited: 66
Second generation androgen receptor antagonists and challenges in prostate cancer treatment
Yanhua Chen, Qianqian Zhou, William Hankey, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 7
Open Access | Times Cited: 64
Rational optimization of a transcription factor activation domain inhibitor
Shaon Basu, Paula Martínez-Cristóbal, Marta Frigolé‐Vivas, et al.
Nature Structural & Molecular Biology (2023) Vol. 30, Iss. 12, pp. 1958-1969
Open Access | Times Cited: 26
PROTACs targeting androgen receptor signaling: Potential therapeutic agents for castration-resistant prostate cancer
Yulu Zhang, Annan Ming, Junyan Wang, et al.
Pharmacological Research (2024) Vol. 205, pp. 107234-107234
Open Access | Times Cited: 8
Androgen receptor monomers and dimers regulate opposing biological processes in prostate cancer cells
Rachid Safi, Suzanne E. Wardell, Paige Watkinson, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 8
Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models
Tatsuo Sugawara, Simon J. Baumgart, Ekaterina Nevedomskaya, et al.
International Journal of Cancer (2019) Vol. 145, Iss. 5, pp. 1382-1394
Open Access | Times Cited: 72
A magic drug target: Androgen receptor
Dan Li, Wenfang Zhou, Jinping Pang, et al.
Medicinal Research Reviews (2018) Vol. 39, Iss. 5, pp. 1485-1514
Closed Access | Times Cited: 65
The Androgen Receptor in Prostate Cancer: Effect of Structure, Ligands and Spliced Variants on Therapy
Elisabeth A. Messner, Thomas M. Steele, Maria Malvina Tsamouri, et al.
Biomedicines (2020) Vol. 8, Iss. 10, pp. 422-422
Open Access | Times Cited: 64
Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond
Simon Linder, Henk G. van der Poel, Andries M. Bergman, et al.
Endocrine Related Cancer (2018) Vol. 26, Iss. 1, pp. R31-R52
Open Access | Times Cited: 63
Effect of Opuntia ficus indica extract on methotrexate-induced testicular injury: a biochemical, docking and histological study
Aziza Akacha, Riadh Badraoui, Tarek Rebaï, et al.
Journal of Biomolecular Structure and Dynamics (2020) Vol. 40, Iss. 10, pp. 4341-4351
Closed Access | Times Cited: 58
Androgens, oestrogens and endometrium: a fine balance between perfection and pathology
Douglas A Gibson, Ioannis Simitsidellis, Frances Collins, et al.
Journal of Endocrinology (2020) Vol. 246, Iss. 3, pp. R75-R93
Open Access | Times Cited: 57
An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer
Michael L. Mohler, Arunima Sikdar, Suriyan Ponnusamy, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 4, pp. 2124-2124
Open Access | Times Cited: 54
A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancer
Lingfan Xu, Yu Yin, Yanjing Li, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 13
Open Access | Times Cited: 51
Structural and molecular determinants of mineralocorticoid receptor signalling
Claudia Großmann, Brian Almeida‐Prieto, Alexander Nolze, et al.
British Journal of Pharmacology (2021) Vol. 179, Iss. 13, pp. 3103-3118
Open Access | Times Cited: 45
Allosteric interactions prime androgen receptor dimerization and activation
Elizabeth V. Wasmuth, Arnaud Vanden Broeck, Justin LaClair, et al.
Molecular Cell (2022) Vol. 82, Iss. 11, pp. 2021-2031.e5
Open Access | Times Cited: 35
Therapeutic Strategies to Target the Androgen Receptor
Weiguo Xiang, Shaomeng Wang
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 13, pp. 8772-8797
Closed Access | Times Cited: 28
International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily—Update 2023
Thomas P. Burris, Ian Mitchelle S. de Vera, Isabelle Côté, et al.
Pharmacological Reviews (2023) Vol. 75, Iss. 6, pp. 1233-1318
Open Access | Times Cited: 19
NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis
Abhijit Parolia, Sanjana Eyunni, Brijesh Kumar Verma, et al.
Nature Genetics (2024)
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top